20 July 2017Americas

Sarepta and Biomarin resolve patent dispute with $35m licence

Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

Under the licence, Sarepta will gain exclusive rights to some of Biomarin’s patents which cover a treatment for patients with Duchenne muscular dystrophy (DMD)

The treatment is called Exondys 51 and is an injection for treatment of DMD.

Announced on Tuesday, July 18, Sarepta’s and BioMarin’s agreement also resolved worldwide patent proceedings concerning the use of Exondys 51.

Sarepta will make a one-time payment of $35 million to BioMarin and pay royalties.

Douglas Ingram, Sarepta’s president, said: “Upon their effectiveness, these global licence and settlement agreements provide Sarepta worldwide freedom to operate for Exondys 51 and our future exon-skipping products.”

He added: “The resolution of these legal matters provides us with more certainty to fully focus our resources and energy on our crucial mission of developing innovative medicines to improve the lives of those impacted by DMD around the world."

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
26 April 2022   BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.

More on this story

Generics
26 April 2022   BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.

More on this story

Generics
26 April 2022   BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.